abigail jenkins headshot

Abigail Jenkins

Chief Commercial & Business Officer 

Abigail Jenkins, M.S., joined Lyndra as the Chief Commercial and Business Officer in 2021.  Ms. Jenkins is a catalyst who helps organizations build towards their next frontier. At Lyndra, she is leading with clarity, connection and courage as the company accelerates from the clinic to the market with the LYNX™ drug delivery platform. As a skilled organizational architect, Ms. Jenkins is leading Lyndra’s commercial, business development and communications functions, and has played a lead role in Lyndra’s corporate strategy, including portfolio prioritization, corporate and platform brand strategy, and market development in central nervous system (CNS) conditions.

Prior to Lyndra, Ms. Jenkins was Senior Vice President and Business Unit Head of Vaccines at Emergent BioSolutions, where she oversaw the company’s largest therapeutic division from discovery through commercialization. She led the team that delivered the largest contract in company history ($2B), as well as the acquisition of a $270M vaccine manufacturer, two market products ($50M incremental net revenue) and a late-stage vaccine asset (est. $350M market potential). She was also a portfolio leader who created the company’s first insight-driven BU portfolio, and led reallocations of $20M in R&D investment and $5M in G&A.

Ms. Jenkins served as Chief Commercial Officer and U.S. Business Head at Aquinox Pharmaceuticals, where she spearheaded efforts to design corporate decision-making framework and governance structures as the company prepared to double in size over a 12-month period leading to 50% company growth. Ms. Jenkins was also a leading member of the executive team driving a $100M capital raise in just over 12 months and led the team that brought a pipeline of new assets from selection to board approval in just six months. She has also held senior market access and business development positions at Relypsa (now Vifor [soon to be CSL]), Actavis (now Teva), Pfizer and Medimmune (now AstraZeneca).

Ms. Jenkins is a dedicated advocate of diversity and equity, both inside the industry and for the patients who use pharmaceuticals. She actively mentors more than 20 up-and-coming women in the industry, both within the Lyndra company program and independently. Ms. Jenkins also works with several diversity-focused non-profits, such as Women in Bio and Boost by BioBreak. She also spent seven years in leadership positions with the Healthcare Businesswomen’s Association (HBA), is a two-time HBA innovation award winner and served on the Interstitial Cystitis Association Board of Directors.

Ms. Jenkins holds a Master of Science in biotechnology and biotech business enterprise from The Johns Hopkins University, a Bachelor of Arts in psychology and biology from Indiana University, and a certificate of achievement in General Management as a Kellogg Executive Scholar. A self-proclaimed fitness fanatic, Ms. Jenkins loves traveling, spending time with her family and well-earned relaxation at the beach.

Member Highlight